AstraZeneca: Imfinzi (Durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in Gastric and Gastroesophageal Junction Cancers in Matterhorn Phase III Trial
June 03, 2023
June 03, 2023
WILMINGTON, Delaware, June 3 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 2, 2023:
Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI(R) (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant (before surgery) chemotherapy demonstrated a statistically significant and clinically meaningful impr . . .
Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI(R) (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant (before surgery) chemotherapy demonstrated a statistically significant and clinically meaningful impr . . .